Johnson & Johnson ( J&J ) is banking on immunology new drugs to fuel its year-over-year growth. Tremfya and Icotide are cited as key drivers of this growth. These drugs belong to the field of highly effective innovative drugs. The article was presented in the context of JPM26, which is a J.P. conference. Morgan Healthcare Conference. The conference takes place from January 12 to 15, 2026 in San Francisco. It is the most important meeting of leaders in the field of health, medicine and investment.